Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on
airway hyperresponsiveness and airway inflammation in mild asthmatics. IMA-026 will be given
as 2 injections under the skin 1 week apart at 2 mg/kg each dose. The study will include a
screening period and a treatment period which includes doses on day 1 and day 8.